Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Exploring Stk3 in Melanoma: A Systematic Review of Signaling Networks and Therapeutic Opportunities Publisher Pubmed



Khanahmadi M1 ; Ebrahimi Fard M3 ; Baghani M4, 7 ; Shayan M5 ; Baghani M4, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Toxicology & amp
  2. 2. Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  3. 3. Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  6. 6. Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Molecular Biology Reports Published:2025


Abstract

Melanoma is an aggressive cancer that disregards both the MAPK and Hippo signaling pathways. This systematic review explores STK3 function in the Hippo pathway to regulate networks and its therapeutic potential in melanoma. From 1991 to 2024, we studied how STK3 interacts with the MAPK/ERK pathway to promote apoptosis and inhibit tumor growth. STK3 controls cell growth, apoptosis, and metastasis via the Hippo and MAPK pathways. It is a melanoma tumor suppressor. Some ways to target STK3 are to directly activate it, stop downstream effectors like YAP/TAZ from working, or use existing BRAF inhibitors together with other methods. Despite advancements, challenges in STK3 drug development persist, warranting further investigation. This review examined the role of STK3 in the development of melanoma and identified potential vulnerabilities for therapeutic intervention. © The Author(s), under exclusive licence to Springer Nature B.V. 2024.
Related Docs
View other Related Docs
1. The Effects of Metformin on the Hippo Pathway in the Proliferation of Melanoma Cancer Cells: A Preclinical Study, Archives of Physiology and Biochemistry (2022)
2. The Hippo Signaling Pathway in Leukemia: Function, Interaction, and Carcinogenesis, Cancer Cell International (2021)
3. Resveratrol As an Antitumor Agent for Glioblastoma Multiforme: Targeting Resistance and Promoting Apoptotic Cell Deaths, Acta Histochemica (2023)
4. Circular Rnas: New Genetic Tools in Melanoma, Biomarkers in Medicine (2020)
5. Exploiting New Strategies in Combating Head and Neck Carcinoma: A Comprehensive Review on Phytochemical Approaches Passing Through Pi3k/Akt/Mtor Signaling Pathway, Phytotherapy Research (2024)
6. A3 Adenosine Receptor Agonist Inhibited Survival of Breast Cancer Stem Cells Via Gli-1 and Erk1/2 Pathway, Journal of Cellular Biochemistry (2017)
7. Mini Review: The Fda-Approved Prescription Drugs That Target the Mapk Signaling Pathway in Women With Breast Cancer, Breast Disease (2021)
8. Synergistic Antitumor Effect of Nvp-Bez235 and Cape on Mda-Mb-231 Breast Cancer Cells, Biomedicine and Pharmacotherapy (2017)
Experts (# of related papers)
View all Related Experts
Shaghayegh Haghjooy Javanmard (2)
Nafiseh Esmaeil (1)
Other Related Docs
9. The Role of Dapk2 As a Key Regulatory Element in Various Human Cancers: A Systematic Review, Molecular Biology Reports (2024)
10. Expression of Mtor/70S6k Signaling Pathway in Melanoma Cancer Cells and the Effects of Dacarbazine and Metformin, Current Cancer Therapy Reviews (2022)
11. The Role of Natural Products As Inhibitors of Jak/Stat Signaling Pathways in Glioblastoma Treatment, Oxidative Medicine and Cellular Longevity (2022)